Table 5 Molecular markers of resistance genotypes for treatment failures observed during therapeutic efficacy monitoring in Angola, 2015
Marker | n (%) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Benguela | Zaire | |||||||||||||||
ASAQ | AL | AL | DP | |||||||||||||
n = 7 | n = 7 | n = 1 | n = 7 | n = 7 | n = 1 | n = 1 | n = 3 | n = 12 | n = 12 | n = 8 | n = 8 | n = 14 | n = 14 | n = 1 | n = 1 | |
Reinf day 0 | Reinf day failure | ETF | Reinf day 0 | Reinf day failure | Recr day 0 | Recr day failure | ETF | Reinf day 0 | Reinf day failure | Recr day 0 | Recr day failure | Reinf day 0 | Reinf day failure | Recr day 0 | Recr day failure | |
K13 | ||||||||||||||||
Wildtype | 7 (100) | 7 (100) | 1 (100) | 7 (100) | 7 (100) | 1 (100) | 1 (100) | 3 (100) | 12 (100) | 12 (100) | 8 (100) | 8 (100) | 14 (100) | 14 (100) | 1 (100) | 1 (100) |
cytB | ||||||||||||||||
Wildtype | 7 (100) | 7 (100) | 1 (100) | 7 (100) | 7 (100) | 1 (100) | 1 (100) | 3 (100) | 12 (100) | 12 (100) | 8 (100) | 8 (100) | 14 (100) | 14 (100) | 1 (100) | 1 (100) |
pfmdr1 a | ||||||||||||||||
NYD | 5 (71) | 5 (71) | 1 (100) | 5 (71) | 5 (71) | – | – | 1 (33) | 7 (58) | 7 (58) | 5 (62) | 5 (62) | 7 (50) | 8 (57) | – | – |
NFD | 1 (14) | 1 (14) | – | 2 (29) | 2 (29) | 1 (100) | 1 (100) | – | 3 (25) | 5 (42) | 3 (38) | 3 (38) | 5 (36) | 4 (29) | 1 (100) | 1 (100) |
YFD | – | – | – | – | – | – | – | – | – | – | – | – | 1 (7) | 1 (7) | – | – |
YYD | 1 (14) | – | – | – | – | – | – | 2 (67) | 2 (17) | – | – | – | 1 (7) | 1 (7) | – | – |
YYY | – | 1 (14) | – | – | – | – | – | – | – | – | – | – | – | – | – | – |